Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Help Your Insusceptibility: Good dieting and Way of life Tips - 2$30K Disability Scam Implodes After Surf Trip in Mexico
- 3Sound Propensities: 20 Methods for helping Your Insusceptible Framework
- 4No injuries after blast at pro-Israel centre in the Netherlands
- 5Investigate Business Mastercard Choices for Better Rewards and Rewards
- 'Something Very Bad Is Going to Happen' is the Duffer Brothers' first project since 'Stranger Things.' It's also 'wildly insane.'
- How do my eyes adjust to the dark and how long does it take?
- Argentina reportedly delaying embassy move over Israeli company's oil project near Falklands
- Vote In favor of Your Favored Distributed computing Administration
- The 1 question we have to ask ourselves about the Taylor Frankie Paul 'Bachelorette' scandal
- Why screening for the deadliest cancer in the U.S. misses most cases
- Investigating Cooking and Culinary Expressions: An Excursion Through Flavors
- French lawmakers narrowly approve health care budget, suspending Macron's flagship pension reform
- Two die and thousands homeless after flooding hits Russia's Dagestan
